A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy

Trial Profile

A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Daratumumab (Primary) ; Bortezomib; Melphalan; Prednisone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms Alcyone
  • Sponsors Genmab; Janssen Biotech; Janssen Research & Development
  • Most Recent Events

    • 12 Dec 2017 Results of interim analysis assessing safety and efficacy published in the New England Journal of Medicine
    • 12 Dec 2017 Results published in the American Society of Hematology Media Release
    • 12 Dec 2017 According to a Janssen Research and Development media release, Dr. Maria-Victoria Mateos, Director of the Myeloma Unit at University Hospital of Salamanca-IBSAL, Salamanca, Spain, is the lead investigator of this trial
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top